Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13735577 | 0.89 | — | — | |
| SCHEMBL16034757 | 0.78 | AR (0.33) | — | |
| SCHEMBL996750 | 0.68 | LOXL2 (0.31) | — | |
| SCHEMBL19204839 | 0.66 | — | — | |
| SCHEMBL20359481 | 0.66 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL18760053 | 0.65 | — | — | |
| SCHEMBL17584302 | 0.64 | — | — | |
| SCHEMBL994930 | 0.63 | LOXL2 (0.42) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2644102 | 0.63 | — | — | |
| SCHEMBL31694531 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323032-B2 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| EP-2861579-B9 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-05-17 | — | — | US | disclosed |
| EP-3321266-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-05-16 | — | — | EP | disclosed |
| US-20180072724-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | US | disclosed |
| EP-3112366-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-28 | — | — | EP | disclosed |
| EP-2861579-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-21 | — | — | EP | disclosed |
| US-9896444-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| EP-2861576-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| EP-2970271-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-08 | — | — | EP | disclosed |
| WO-2014152589-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275120-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-8829195-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| WO-2013171639-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-20130310395-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| WO-2013171642-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| EP-2454253-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | Merck Patent GmbH (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006567-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323032-B2 | P2X7 Modulators | P2RX7, P2RX1, P2RX3 | ALDH1A1 1245/4885CYP3A4 714/4885CYP2D6 550/4885 |
| US-20140275120-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | ALDH1A1 1351/4885CYP3A4 642/4885CYP2D6 496/4885 |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | PDK1, PDK2, PDK4 | ALDH1A1 1341/4885CYP3A4 2520/4885CYP2D6 3099/4885 |
| US-20130310395-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ALDH1A1 1602/4885CYP3A4 2284/4885CYP2D6 1651/4885 |
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ALDH1A1 1181/4885CYP3A4 1541/4885CYP2D6 1447/4885 |
| US-20180072724-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | ALDH1A1 1245/4885CYP3A4 714/4885CYP2D6 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.